GERN / Why Is Geron (GERN) Stock Soaring 50% Today?

Geron Corporation stock has nearly halved since July, leading to concerns about whether the price will go back up. Geron's telomerase inhibitor imetel more_horizontal

Sell-off in Geron Corp (NASDAQ: GERN) over the past three months has created a great buying opportunity, says Corinne Jenkins – a Goldman Sachs anal more_horizontal

Geron (NASDAQ: GERN ) stock is gaining on Tuesday following an upgrade for the biopharmaceutical company's shares. Goldman Sachs analyst Corinne Jenki more_horizontal

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. more_horizontal

Geron Corporation (GERN) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, GERN's 50 more_horizontal

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that five abs more_horizontal

Geron's imetelstat has shown promise to treat a rare blood disorder. The drug could have wide oncology applications. more_horizontal

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. more_horizontal